SeraCare is part of LGC Clinical Diagnostics - Learn More

The BRCA 1 and BRCA 2 tumor suppressors genes limit DNA
damage, consequently, loss of function mutations in these genes
lead to increased incidence of breast, ovarian, and prostate cancer.
Accurate detection of BRCA variants is thus of paramount
importance for patients with somatic cancer to guide treatment
strategies, such as eligibility for PARP inhibitor therapy, and for
individuals carrying inherited mutations to consider preventive

Download this scientific poster to learn how newly developed reference materials to support both BRCA1 and BRCA2 inherited and somatic genetic testing, can provide your laboratories and assay developers with tools to challenge and optimize their assay’s detection and quantitation of pathogenic variants by NGS. 


To download, fill out the form and you will receive an email with the content.

AACR 2023 SP - Multi site evaluation of novel BRCA12 reference materials including genomic rearragements
Scroll to top